Sagimet Accumulated Other Comprehensive Income from 2010 to 2024
| SGMT Stock | 4.89 0.16 3.17% |
Accumulated Other Comprehensive Income | First Reported 2010-12-31 | Previous Quarter 30 K | Current Value 31.5 K | Quarterly Volatility 73.5 M |
Check Sagimet Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sagimet Biosciences' main balance sheet or income statement drivers, such as Net Interest Income of 1.8 M, Interest Income of 1.8 M or Depreciation And Amortization of 18.8 M, as well as many indicators such as Price To Sales Ratio of 22.68, Dividend Yield of 0.0 or PTB Ratio of 0.65. Sagimet financial statements analysis is a perfect complement when working with Sagimet Biosciences Valuation or Volatility modules.
Sagimet | Accumulated Other Comprehensive Income |
Latest Sagimet Biosciences' Accumulated Other Comprehensive Income Growth Pattern
Below is the plot of the Accumulated Other Comprehensive Income of Sagimet Biosciences Series over the last few years. It is gains and losses not included in net income that are recorded in shareholders' equity, reflecting changes in the value of assets or liabilities that are not realized. Sagimet Biosciences' Accumulated Other Comprehensive Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sagimet Biosciences' overall financial position and show how it may be relating to other accounts over time.
| Accumulated Other Comprehensive Income | 10 Years Trend |
|
Accumulated Other Comprehensive Income |
| Timeline |
Sagimet Accumulated Other Comprehensive Income Regression Statistics
| Arithmetic Mean | (27,836,233) | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | (264.00) | |
| Mean Deviation | 48,246,471 | |
| Median | 0.00 | |
| Standard Deviation | 73,488,529 | |
| Sample Variance | 5400.6T | |
| Range | 214.7M | |
| R-Value | (0.32) | |
| Mean Square Error | 5224.6T | |
| R-Squared | 0.10 | |
| Significance | 0.25 | |
| Slope | (5,240,034) | |
| Total Sum of Squares | 75607.9T |
Sagimet Accumulated Other Comprehensive Income History
About Sagimet Biosciences Financial Statements
Sagimet Biosciences shareholders use historical fundamental indicators, such as Accumulated Other Comprehensive Income, to determine how well the company is positioned to perform in the future. Although Sagimet Biosciences investors may analyze each financial statement separately, they are all interrelated. The changes in Sagimet Biosciences' assets and liabilities, for example, are also reflected in the revenues and expenses on on Sagimet Biosciences' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 30 K | 31.5 K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Sagimet Stock Analysis
When running Sagimet Biosciences' price analysis, check to measure Sagimet Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sagimet Biosciences is operating at the current time. Most of Sagimet Biosciences' value examination focuses on studying past and present price action to predict the probability of Sagimet Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sagimet Biosciences' price. Additionally, you may evaluate how the addition of Sagimet Biosciences to your portfolios can decrease your overall portfolio volatility.